Skip to search formSkip to main contentSkip to account menu

masitinib

Known as: 4-((4-methylpiperazin-1-yl)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)-1,3-thiazol-2-yl)amino)phenyl)benzamide, masatinib 
National Institutes of Health

Related topics

Related topics

9 relations

Narrower (3)

AB 1010kinavet CA-1masivet
Inhibition of Cell ProliferationPositive Regulation of ApoptosisReceptor Tyrosine Kinase InhibitionSignal Transduction Inhibition

Broader (1)

Thiazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
FDA approves first new ALS drug in over 20 years
2016
2016
Oral tyrosine kinase inhibitor masitinib in combination with gemcitabine in patients with advanced pancreatic cancer: A multicenter phase II study.
4617 Background: Masitinib, a tyrosine kinase inhibitor targeting c-Kit, PDGFR, FGFR3 and affecting the FAK pathway, can enhance… 
Review
2016
Review
2016
A retrospective review of treatment and response of high-risk mast cell tumours in dogs.
This retrospective case series evaluates survival outcome of 94 dogs with high metastatic risk mast cell tumours (MCT). Patients… 
Review
2015
Review
2015
C-kit as a prognostic and therapeutic marker in canine cutaneous mast cell tumours: From laboratory to clinic.
Review
2014
Review
2014
Small molecule inhibitors in veterinary oncology practice.
2013
2013
Masitinib in nonresectable pancreatic cancer: Results of a phase III randomized placebo-controlled trial.
158 Background: Masitinib is a selective c-Kit inhibitor that efficiently inhibits mast cell function. Increased mast cell… 
2013
2013
Masitinib-associated minimal change disease with acute tubular necrosis resulting in acute kidney injury in a dog.
A 10-year-old spayed female Labrador Retriever was brought to the Heart of Texas Veterinary Specialty Center for additional… 
2011
2011
Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial.
This study investigated the efficacy and safety of masitinib, a selective tyrosine kinase inhibitor capable of downregulating… 
2009
2009
Pharmacokinetics of masitinib in cats
Masitinib is the first veterinary drug recently approved in Europe to treat mast cell tumours in dogs (Hahn et al. JVIM, Masivet… 
2007
2007
Preliminary efficacy and safety results of masitinib administered, front line in patients with advanced GIST. A phase II study
10025 Background: Masitinib mesylate (MM; AB1010) is a protein tyrosine kinase inhibitor (tki) which, in vitro, has greater… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)